In the past decade, the power of harnessing T-cell co-signaling pathways has become increasingly understood to have significant clinical importance. In cancer immunotherapy, the field has concentrated on two related modalities: First, targeting cancer antigens through highly activated chimeric antigen T cells (CAR-Ts) and second, re-animating endogenous quiescent T cells through checkpoint blockade. In each of these strategies, the therapeutic goal is to re-ignite T-cell immunity, in order to eradicate tumors. In transplantation, there is also great interest in targeting T-cell co-signaling, but with the opposite goal: in this field, we seek the Yin to cancer immunotherapy's Yang, and focus on manipulating T-cell co-signaling to induce tolerance rather than activation. In this review, we discuss the major T-cell signaling pathways that are being investigated for tolerance induction, detailing preclinical studies and the path to the clinic for many of these molecules. These include blockade of co-stimulation pathways and agonism of coinhibitory pathways, in order to achieve the delicate state of balance that is transplant tolerance: a state which guarantees lifelong transplant acceptance without ongoing immunosuppression, and with preservation of protective immune responses. In the context of the clinical translation of immune tolerance strategies, we discuss the significant challenge that is embodied by the fact that targeted pathway modulators may have opposing effects on tolerance based on their impact on effector vs regulatory T-cell biology. Achieving this delicate balance holds the key to the major challenge of transplantation: lifelong control of alloreactivity while maintaining an otherwise intact immune system.
Bibliographical noteFunding Information:
This work was supported by NHLBI 5 R01 HL095791, NIAID 5U19-AI051731 (L. S. K.), 2R01 HL56067, R01 AI 34495, R01 HL11879, and P01 AI 056299, 2P01 CA065493 (B. R. B.). P01 HL018646; P01 AI056299; UM1AI109565 (L. A. T.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
- co-inhibitory blockade
- co-stimulation blockade